METROMILE INC (MILE)

US5916971071 - Common Stock

1.05  +0.07 (+7.67%)

After market: 1.02 -0.03 (-2.86%)

Fundamental Rating

2

Taking everything into account, MILE scores 2 out of 10 in our fundamental rating. MILE was compared to 140 industry peers in the Insurance industry. MILE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MILE is valued expensive and it does not seem to be growing.



0

1. Profitability

1.1 Basic Checks

MILE had negative earnings in the past year.

1.2 Ratios

Industry RankSector Rank
ROA -49.8%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Operating Margin and Gross Margin are not available for MILE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) -135.85%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

4

2. Health

2.1 Basic Checks

MILE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MILE has been increased compared to 1 year ago.
There is no outstanding debt for MILE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

There is no outstanding debt for MILE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC7.55%

2.3 Liquidity

Industry RankSector Rank
Current Ratio N/A
Quick Ratio N/A

3

3. Growth

3.1 Past

The earnings per share for MILE have decreased strongly by -9949.68% in the last year.
EPS 1Y (TTM)-9949.68%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q80.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q19.81%

3.2 Future

MILE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.03% yearly.
MILE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 29.64% yearly.
EPS Next Y62.43%
EPS Next 2Y32.18%
EPS Next 3Y18.29%
EPS Next 5Y11.03%
Revenue Next Year21.19%
Revenue Next 2Y30.12%
Revenue Next 3Y29.37%
Revenue Next 5Y29.64%

3.3 Evolution

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MILE. In the last year negative earnings were reported.
Also next year MILE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -0.35

4.3 Compensation for Growth

A more expensive valuation may be justified as MILE's earnings are expected to grow with 18.29% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.18%
EPS Next 3Y18.29%

0

5. Dividend

5.1 Amount

No dividends for MILE!.
Industry RankSector Rank
Dividend Yield N/A

METROMILE INC

NASDAQ:MILE (7/27/2022, 7:12:46 PM)

After market: 1.02 -0.03 (-2.86%)

1.05

+0.07 (+7.67%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupInsurance
GICS IndustryInsurance
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap136.94M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -49.8%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) -135.85%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio N/A
Quick Ratio N/A
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-9949.68%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y62.43%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y